TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC 50 and a K i of 1.5 nM and 11.9 nM, respectively TL-895 is used be for JAKi-relapsed/refractory myelofibrosis, acute myeloid leukemia, COVID-19 and cancer research
Form:Solid
IC50& Target:IC50: 1.5 nM,Ki: 11.9 nM (BTK)
规格
规格或纯度
≥99%
英文名称
TL-895
生化机理
TL-895 是一种强效、口服活性、ATP 竞争性和高选择性的不可逆 BTK 抑制剂,其 IC 50 和 K i 分别为 1.5 nM 和 11.9 nM。TL-895 可用于治疗 JAKi- 复发/难治性骨髓纤维化、急性髓性白血病、COV